HERE0:4

biotech stocks

3 Biotech Stocks Are Getting Crushed: Genocea Biosciences Inc(NASDAQ:GNCA …

“For the time being, we are removing the development of GEN-004 from our near-term plans to focus our resources on the ongoing Phase 2 program for GEN-003, our immunotherapy for genital herpes, for which we recently announced positive six-month …

7
Like
Save
Biotech Stocks With Optimistic Trend – Genocea Biosciences Inc (NASDAQ:GNCA …

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

4
Like
Save
Biotech Stocks with Active Concerns: Genocea Biosciences, Inc. (NASDAQ:GNCA …

… cell-directed vaccines and immunotherapies, recently reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of …

3
Like
Save
3 Biotech Stocks Getting Some Love -Genocea Biosciences Inc (NASDAQ:GNCA …

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

6
Like
Save
Cowen Offers Commentary on Two Biotech Stocks: MEI Pharma Inc (MEIP), Genocea …

However, if achieved it could increase GEN-003's penetration of the genital herpes market and/or increase Genocea's pricing power. These factors would represent upside to our model.” According to TipRanks.com, which measures analysts' and bloggers' …

3
Like
Save
Biotech Stocks that your portfolio will love – BioTime, Inc. (NYSEMKT:BTX …

The company, on June 22, 2015, reported top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in …

8
Like
Save
Investors Dumping 3 Biotech Stocks – Vical Incorporated (NASDAQ:VICL …

The company, on June 22, 2015, released top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in …

4
Like
Save
Biotech Stocks Touched New Lows: Synta Pharmaceuticals (NASDAQ:SNTA …

On 7 January Genocea Biosciences, Inc. (NASDAQ:GNCA) reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line data from the …

7
Like
Save